THE STABILIZATION OF VANCOMYCIN BY PEPTIDOGLYCAN ANALOGS

Constance M. Harris, Hana Kopecka and Thomas M. Harris

Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37235, USA

(Received for publication May 26, 1984)

The glycopeptide antibiotic vancomycin is unstable in solution. It undergoes a rearrangement involving the conversion of an asparagine residue to isoaspartate to give an antibiologically inactive species, CDP-I. Peptide analogs of bacterial peptidoglycan, such as Ac-D-Ala-D-Ala and di-Ac-L-Lys-D-Ala-D-Ala bind to vancomycin and stabilize the antibiotic against degradation and consequent loss of activity. Protection by peptide is effective even under prolonged heating at 80°C or steam sterilization (30 minutes, 10^6 kg/m^2).

Vancomycin (1), a glycopeptide antibiotic elaborated by Streptomyces orientalis is used clinically for treatment of methicillin-resistant Staphylococcus aureus infections and Clostridium difficile-induced colitis. The structure of this relatively large (MW 1,447) natural product has interested chemists since its isolation in 1956, although only recently was the structure fully defined. Structure elucidation was hindered by failure of the antibiotic to give crystals suitable for analysis by X-ray crystallography, but eventually a crystal structure was obtained for CDP-I, an antibiologically inactive hydrolysis product of the antibiotic. CDP-I was subsequently shown by Williamson and Williams to exist in two forms, major (CDP-I-M, 2) with the chlorine on ring 2 on the front or concave side of the molecule and minor (CDP-I-m, 3) with the chlorine on the back or convex side, as it is in vancomycin. Formation of CDP-I was initially believed to involve simple hydrolysis of an isoasparagine residue to an isoaspartate but work in our laboratory subsequently showed that a rearrangement of the peptide...
backbone was occurring in which an asparagine residue rearranged via a cyclic imide to an isoaspartate. The rearrangement expands the cyclophane ring in which residue 2 is embedded so that the aromatic ring of residue 2 can rotate to bring the chloro substituent to the front side of the antibiotic, leading to an equilibrium mixture of the major and minor forms of CDP-I (approximately 2:1 at 25°C), hereafter referred to as CDP-I. Two incorrect structures for vancomycin were proposed before this rearrangement was discovered\(^7,8\). Although there are a number of other antibiotics, such as ristocetin, actinoidin, avoparcin, A35512B, the actaplanins and teichomycin A\(_2\) which are closely related, vancomycin is the only one known to contain an asparagine.

Conversion of vancomycin into CDP-I is a facile process which occurs near neutrality and at rates much higher than those for hydrolysis of simple amides or normal peptide linkages. Indeed, unique structural features of the vancomycin molecule must play a key role in the rearrangement because the reaction has not been observed in other asparagine-containing peptides and proteins under similar reaction conditions. The instability of vancomycin is of interest to clinicians as well as organic chemists because the drug must be stored in dry form although aqueous solutions are employed for oral and intravenous administration. Even with refrigeration, solutions have been reported to have limited shelf lives\(^{10,11}\).

We now report that certain peptides which complex with vancomycin inhibit CDP-I formation. Studies of the mechanism of action of vancomycin have revealed its ability to complex with peptide constituents of bacterial peptidoglycan\(^{12,13}\). In the early 1970's, prior to significant structural information being available about vancomycin, NIETO and PERKINS\(^5\) mapped out many of the structural features of peptides necessary for complex formation with the antibiotic. The binding process was initially studied by ultraviolet difference spectroscopy; more recently high field NMR using measurements of nuclear Overhauser effects and chemical shift changes has been employed to identify the peptide binding
In our first experiment, three aqueous samples of vancomycin (1 mM, pH 4.2) were stored at room temperature. Stoichiometric quantities of Ac-D-Ala-D-Ala (4) and di-Ac-L-Lys-D-Ala-D-Ala (5) were added to two of the samples while the remaining one served as a control. After three months, the solutions were assayed by HPLC. Whereas the control had undergone 20% conversion to CDP-I, essentially no rearrangement had occurred in the samples to which the peptides had been added.

Next a more detailed study was made at 80°C using solutions which had been adjusted to pH 6.0. Table 1 shows that 50% of the vancomycin in the control sample had rearranged to CDP-I whereas only 23% decomposition had occurred in the presence of one equivalent of dipeptide 4. Two equivalents of the dipeptide were more effective, reducing the observed decomposition to only 8%.

Although no difference was detected at room temperature, tripeptide 5 provides more effective protection at 80°C than the dipeptide. Only 10% degradation was observed in the presence of a stoichiometric quantity of tripeptide and, with two equivalents of 5, no degradation was observed. On the other hand, only slight protection was provided by Ac-D-Ala-Gly or by Ac-Gly-D-Ala; 39% and 28% decomposition was observed in the presence of stoichiometric quantities of the respective peptides in 1 mM solutions. Ac-D-Ala-β-Ala and Ac-D-Ala-aminoisobutyric acid provided no discernible protection.

The degree of protection by these peptides correlates well with the binding affinities of the peptides for the antibiotic; values of the association constants reported by NIETO and PERKINS14) are tabulated in Table 1 for the four peptides that showed varying amounts of protection. The other two peptides exhibited very weak binding when UV difference titrations were carried out in the manner described by those workers.

These results demonstrate definitively the ability of the binding peptides to inhibit CDP-I formation. The procedure would have value for stabilizing vancomycin solutions if it does not interfere with antibiotic activity. A test of this question was made with dipeptide 4 using vancomycin solutions.
that had been heated at 80°C for 66 hours (see Table 2). Under these conditions, HPLC analysis indicated 63% conversion of a 1 mM solution of vancomycin to CDP-I; antibiotic assay with Bacillus subtilis showed that only 25% of the antibiotic activity remained. In the presence of two equivalents of dipeptide 4, only 13% degradation occurred, as measured by HPLC and loss of activity. With unheated controls, with and without dipeptide, no CDP-I formation could be detected nor was any loss of antibiotic activity observed. On one hand the dipeptide is effective in stabilizing the antibiotic while on the other it does not inhibit antibiotic activity, even though both processes probably involve the same binding site on the antibiotic. The explanation for this paradoxical result is that the thermal degradation studies were conducted with solutions (1 mM) which were sufficiently concentrated so that most of the vancomycin was present in the bound form. The association constant shown in Table 1 was measured at 25°C; binding constants decrease with temperature and a value of 4 x 10³ can be estimated for dipeptide 4 at 80°C. Thus approximately 60% of the vancomycin would be expected to be in the bound form at 80°C. For the antibiotic assay these solutions were diluted by a factor of 20 to 200 leading to substantial dissociation of the peptide complex even at room temperature. Furthermore, the dipeptide represents only a portion of the structure of the cellular receptors for the antibiotic and as a consequence probably has a lower affinity for the antibiotic than does the natural substrate.

As a final experiment, peptide protection was evaluated (see Table 3) under conditions of steam sterilization (10³ kg/m², 121°C). Again using 1 mM solutions, extensive loss of antibiotic activity (42%) occurred during 30 minutes of heating the antibiotic in the absence of peptide. Dipeptide 4 provided only partial protection, affording 70 and 81% retention of antibiotic activity after heat treatment using 1 and 2 equivalents of dipeptide. The decreased effectiveness of dipeptide reflects a higher rate of decomposition coupled with a lower affinity constant at that temperature. It is noteworthy that with tripeptide 5, which binds vancomycin somewhat more efficiently (estimated $K_{assoociation}$ at 121°C: 1.2 x 10⁴)¹⁰, no loss of antibiotic activity was observed.

The mechanism of CDP-I formation involves cyclization of the asparagine residue by attack of the C-1 amide nitrogen on the C-4 carbonyl group to give a cyclic imide which cleaves by water attack ex-

### Table 2. Protection of antibiotic activity by Ac-D-Ala-D-Ala.

<table>
<thead>
<tr>
<th>Sample</th>
<th>% Degradation</th>
<th>% Antibiotic activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin-unheated</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Vancomycin-heated</td>
<td>63</td>
<td>25</td>
</tr>
<tr>
<td>Vancomycin+Ac-D-Ala-D-Ala (1: 2) unheated</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Vancomycin+Ac-D-Ala-D-Ala (1: 2) heated</td>
<td>13</td>
<td>87</td>
</tr>
</tbody>
</table>

Solutions (2 ml) contained vancomycin (1 mM) and peptide (2 mM) at an initial pH of 4.40. Heating was carried out for 66 hours at 80°C. Analysis for degradation was carried out by HPLC (Altex or IBM C-18 column, gradient elution with 7.75% CH₃CN - 0.1 M ammonium formate (pH 6.05) to 18.75% CH₃CN - 0.1 M ammonium formate (pH 6.20), 2 ml/minute). Antibiotic activity was assayed by disc diffusion on agar using B. subtilis as the test organism.

### Table 3. Protection of vancomycin by peptides under steam sterilization conditions.

<table>
<thead>
<tr>
<th>Additive</th>
<th>% Antibiotic activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>58</td>
</tr>
<tr>
<td>Ac-D-Ala-D-Ala (1: 1)</td>
<td>70</td>
</tr>
<tr>
<td>Ac-D-Ala-D-Ala (2: 1, peptide: antibiotic)</td>
<td>81</td>
</tr>
<tr>
<td>Di-N-Ac-L-Lys-D-Ala-D-Ala (1:1)</td>
<td>98</td>
</tr>
</tbody>
</table>

Solutions contained vancomycin (1 mM) and peptide in the indicated ratio, initial pH 4.2~4.3. They were steam sterilized for 30 minutes at 10³ kg/m² and then assayed for antibiotic activity by disc diffusion on agar.
elusively at the C-1 carbonyl group to leave an isoaspartate residue in the peptide chain (Fig. 1). The process by which peptides 4 and 5 complex with vancomycin has been postulated to involve hydrogen bonding of the carboxylate anion of the peptide to a nest of NH groups as shown in Fig. 2.\(^{19-20}\) The cluster is made up of the terminal ammonium ion and the NH groups of the first three peptide bonds, \textit{i.e.}, the nest includes both peptide linkages of the asparagine residue but not the 4 carboxamide. The resulting nested structure is sterically incompatible with imide formation both when bonded to peptide and when free. Cyclic imide is formed from a more extended conformation. The imide is not capable of binding peptide, not just because one NH hydrogen bonding site has been lost but because the extended conformation places the remaining carboxylic pocket too far from the receptor sites on the other end of the antibiotic molecule, so that the peptide is unable to complex simultaneously to both ends. Consequently, to the extent that free vancomycin is in equilibrium with bound material, succinimide formation can occur followed by irreversible ring opening.

Experimental

Vancomycin was obtained from Eli Lilly and used without further purification. Ac-D-Ala-D-Ala (4), \textit{d}-Ac-I-Lys-D-Ala-D-Ala (5), Ac-D-Ala-Gly, and Ac-Gly-D-Ala were prepared according to \textsc{Nieto} and \textsc{Perkins}\(^{14}\). Ac-D-Ala-aminoisobutyric acid and Ac-D-Ala-\textit{b}-Ala were prepared by similar methodology.

\textsc{Ac-D-Ala-\textit{b}-Ala:} MP; 133.5 \textendash; 134.5°C (EtOH - hexane).

\textit{Anal Calcd} for C\(_8\)H\(_{14}\)N\(_2\)O\(_4\): C 47.52, H 6.98.

\textit{Found:} C 47.75, H 7.12.

\([\alpha]_D^\text{a} +52^\circ\) (c 0.54, MeOH).

\textit{H NMR} (90 MHz, MeOH-\(d_4\)) \(\delta\) 4.27 (1H, q, \(J=8\) Hz), 3.41 (2H, t, \(J=7\) Hz), 2.49 (2H, t, \(J=7\) Hz), 1.95 (3H, s), 1.30 (3H, d, \(J=8\) Hz).

\textsc{Ac-D-Ala-aminoisobutyric Acid:} MP; 163 \textendash; 164.5°C (EtOH - hexane).

\textit{Anal Calcd} for C\(_8\)H\(_{16}\)N\(_2\)O\(_4\): C 49.99, H 7.46.

\textit{Found:} C 50.00, H 7.32.

\([\alpha]_D^\text{a} +74^\circ\) (c 0.5, MeOH).

\textit{H NMR} (90 MHz, MeOH-\(d_4\)) \(\delta\) 4.32 (1H, q, \(J=8\) Hz), 1.95 (3H, s), 1.48 (3H, s), 1.46 (3H, s), 1.30 (3H, d, \(J=8\) Hz).

Solutions containing antibiotic or antibiotic plus peptide were adjusted to the desired pH, placed in screw-capped culture tubes (16 × 125 mm) with Teflon-lined caps and heated in a Reacti-Therm block (Pierce Chemical Company). If precipitate was present at the end of the heating period, 10 \(\mu\)l of trifluoroacetic acid was added before HPLC analysis.

HPLC analysis was carried out either with a Spectra Physics Model 8700 system or an IBM Model 9533 ternary gradient liquid chromatograph with detection at 254 nm. C-18 columns (Altex or IBM,
Gradient elution was performed using 7.75% CH₃CN - 0.1 M ammonium formate (pH 6.05) to 18.75% CH₃CN - 0.1 M ammonium formate (pH 6.20) over 15 minutes, 2 ml/minute. Subsequently, it was found that use of an Altex C-18 column (10 x 250 mm) with elution by 13.5% CH₃CN - 0.1% TFA gave superior resolution and more satisfactory integration, although the first separation system was adequate for the experiment described. Integration was carried out gravimetrically. For the purposes of this paper only peaks corresponding to vancomycin, CDP-I-M and CDP-I-m were evaluated. The % vancomycin was calculated as:

\[
\% \text{Vancomycin} = \frac{\text{Vancomycin}}{\text{Vancomycin} + \text{CDP-I-M} + \text{CDP-I-m}} \times 100
\]

and the % degradation:

\[
\% \text{Degradation} = \frac{\% \text{Vancomycin in reaction mixture}}{\% \text{Vancomycin in standard}}
\]

HPLC analysis of the commercial vancomycin preparation used in these experiments indicated a 9% contamination by CDP-I species. Other more minor constituents were present, none greater than 5%. Several of these were tentatively identified as mono- and didechlorovancomycin and their CDP-type rearrangement products by HPLC comparison with authentic samples. These were ignored in the present studies.

Antibiotic assays were carried out by the disc diffusion method\(^{21,25}\) with B. subtilis (Difco) as the test organism. Assays were run in triplicate with each plate containing four concentrations of unknown and four of a standard vancomycin solution (66 µg/ml to 6.6 µg/ml). A graph of the diameter of inhibition zone vs. ln(c) was plotted and the concentration of unknown needed to produce an inhibition zone of 16 mm was measured. The % antibiotic activity is defined as:

\[
\% \text{Antibiotic Activity} = \frac{\text{Diameter of inhibition zone of unknown}}{\text{Diameter of inhibition zone of standard}} \times 100
\]
References


Acknowledgments

We thank K. RAJAMOORTHI for the determination of binding constants for Ac-d-Ala-β-Ala and Ac-d-Ala-aminobutyric acid and the U.S. Public Health Service for generous financial support (grant No. GM-23593).